Literature DB >> 19348888

Chapter 9 Reliable assay for measuring complex I activity in human blood lymphocytes and skin fibroblasts.

L Elly A de Wit1, Wim Sluiter.   

Abstract

Complex I deficiency is probably the most common enzyme defect among the group of OXPHOS disorders. To evaluate a deficiency of complex I activity, biochemical measurements based on estimation of the mitochondrial rotenone-sensitive NADH: ubiquinone oxidoreductase activity are an important tool. Skeletal muscle is the most widely used tissue to examine complex I deficiency. However, obtaining a muscle biopsy requires an invasive surgical operation. It is much easier to obtain blood lymphocytes or skin fibroblasts, and, moreover, these cells can be expanded in number by standard techniques for extensive research on complex I. On the other hand, each of these cell types has disadvantages that hinder its measurement, such as the apparent low enzyme activity of lymphocytes and the highly contaminating nonmitochondrial NADH-quinone oxidoreductase activity of fibroblasts. This chapter describes a method to assay complex I activity reliably in a minute amount of either cell type.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19348888     DOI: 10.1016/S0076-6879(08)04409-1

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  7 in total

1.  Coenzyme Q(1) as a probe for mitochondrial complex I activity in the intact perfused hyperoxia-exposed wild-type and Nqo1-null mouse lung.

Authors:  Robert D Bongard; Charles R Myers; Brian J Lindemer; Shelley Baumgardt; Frank J Gonzalez; Marilyn P Merker
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-20       Impact factor: 5.464

2.  Mice lacking TR4 nuclear receptor develop mitochondrial myopathy with deficiency in complex I.

Authors:  Su Liu; Yi-Fen Lee; Samuel Chou; Hideo Uno; Gonghui Li; Paul Brookes; Michael P Massett; Qiao Wu; Lu-Min Chen; Chawnshang Chang
Journal:  Mol Endocrinol       Date:  2011-05-26

3.  Reduction of infarct size by the therapeutic protein TAT-Ndi1 in vivo.

Authors:  Robert M Mentzer; Joseph Wider; Cynthia N Perry; Roberta A Gottlieb
Journal:  J Cardiovasc Pharmacol Ther       Date:  2013-12-23       Impact factor: 2.457

4.  Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity.

Authors:  Ruud C W Vermeulen; Ruud M Kurk; Frans C Visser; Wim Sluiter; Hans R Scholte
Journal:  J Transl Med       Date:  2010-10-11       Impact factor: 5.531

5.  Defective complex I assembly due to C20orf7 mutations as a new cause of Leigh syndrome.

Authors:  M Gerards; W Sluiter; B J C van den Bosch; L E A de Wit; C M H Calis; M Frentzen; H Akbari; K Schoonderwoerd; H R Scholte; R J Jongbloed; A T M Hendrickx; I F M de Coo; H J M Smeets
Journal:  J Med Genet       Date:  2009-06-18       Impact factor: 6.318

6.  Nitric oxide synthesis is increased in cybrid cells with m.3243A>G mutation.

Authors:  Juliana Gamba; Luana T Gamba; Gabriela S Rodrigues; Beatriz H Kiyomoto; Carlos T Moraes; Celia H Tengan
Journal:  Int J Mol Sci       Date:  2012-12-24       Impact factor: 5.923

7.  Exercise-induced mitochondrial p53 repairs mtDNA mutations in mutator mice.

Authors:  Adeel Safdar; Konstantin Khrapko; James M Flynn; Ayesha Saleem; Michael De Lisio; Adam P W Johnston; Yevgenya Kratysberg; Imtiaz A Samjoo; Yu Kitaoka; Daniel I Ogborn; Jonathan P Little; Sandeep Raha; Gianni Parise; Mahmood Akhtar; Bart P Hettinga; Glenn C Rowe; Zoltan Arany; Tomas A Prolla; Mark A Tarnopolsky
Journal:  Skelet Muscle       Date:  2016-01-31       Impact factor: 4.912

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.